Pathways Preclinical Partners and abc biopply Forge Strategic Collaboration to Advance Human-Relevant Preclinical Innovation
Newark, DE & Solothurn, Switzerland — January 27, 2026 — Pathways Preclinical Partners (“Path2P”) and abc biopply AG today announced a new collaboration aimed at enhancing the integration of abc biopply’s cutting-edge preclinical NAM technology 3D CoSeedis™ within global drug development networks.
Under this initiative, Pathways Preclinical Partners will support the broader introduction of abc biopply’s advanced humanized disease model technology throughout its professional network and contribute to programs that drive translational impact for life-science innovators.
Path2P is a strategic consulting firm dedicated to guiding pharmaceutical and biotech companies through complex development pathways, from late-stage preclinical work to firstin-human clinical readiness, by providing regulatory, commercialization, and business development strategies tailored to scientific goals and market realities. Its expert team includes former regulatory officials and industry leaders who help clients make informed decisions and accelerate their path to patients.
abc biopply AG, a Swiss biotech pioneer, offers highly predictive preclinical CRO services grounded in its proprietary 3D CoSeedis™ Multi-Organoid in Chip Technology, enabling scalable and standardized humanized multi-organoid disease models across therapeutic areas such as oncology, neurology, hepatology and others. These models were created to close the translational gap between simple, high-throughput 2D and 3D in vitro systems and complex in vivo models with low throughput. A major limitation in predictability today results from the lack of translational applicability of the results from the two model types. abc biopply’s new NAM technology provides early accessibility of fully scalable, complex models with high throughput capabilities, enhancing physiological relevance while reducing the consumption of time, costs, and animal resources.
“Pathways is excited to bring abc biopply’s transformative organoid technology to our network and contribute to the future of human-relevant preclinical innovation,” said Jae Sly, MBA, PhD, Chairman & CEO of Pathways Preclinical Partners. “This collaboration highlights our shared commitment to empowering biotech and pharmaceutical innovators with tools and strategies that de-risk development and contribute to meaningful patient impact.”
By supporting the accessibility and understanding of advanced humanized preclinical models, the collaboration aims to help scientists, developers, and decision-makers explore more physiologically relevant alternatives in the drug discovery process, while fostering connections that accelerate translational success.
“We are looking forward to working alongside Pathways to bring our technology into new scientific and commercial forums,” said Dr. Arne Faisst, Founder & CEO of abc biopply AG. “Our shared vision around improving preclinical predictability aligns closely with global needs for more humanized approaches in therapeutic development.”
The collaboration underscores the increasing importance of innovative preclinical platforms and strategic guidance in driving efficiency and confidence across drug development pipelines. By bridging expertise in advanced modeling and global networking, both organizations are positioned to impact how next-generation therapies are evaluated and advanced toward clinical application.
For more information about Pathways Preclinical Partners, visit https://www.path2p.com.
Pathways Preclinical Partners, Inc
591 Collaboration Way
STE 613
Newark, DE 19713
To learn more about abc biopply and its 3D CoSeedis technology, visit https://biopply.com.
abc biopply ag
Weissensteinstrasse 81
CH-4500 Solothurn
Switzerland